

Products list > Product patents

Product patents

In accordance with Section 287(a) of Title 35 of the United States Code, the following list identifies Merck’s rights in U.S. patents associated with the relevant product. This list may be a subset of Merck’s rights in U.S. patents directed to the relevant product.

- Animal health
- Prescription pharmaceuticals
- Vaccines

BELSOMRA®
(suvorexant) Tablets
U.S. Patent No. 7,951,797
U.S. Patent No. 10,098,892

BRIDION®
(sugammadex sodium injection) For intravenous use
U.S. Patent No. RE44,733

DELSTRIGO®
(doravirine/lamivudine/tenofovir disoproxil fumarate) Tablets
U.S. Patent No. 8,486,975
U.S. Patent No. 10,603,282
U.S. Patent No. 10,842,751



DIFICID®
(fidaxomicin) for Oral Suspension
U.S. Patent No. 7,863,249
U.S. Patent No. 7,378,508
U.S. Patent No. 9,808,530

DIFICID®
(fidaxomicin) Tablets for oral use

Halozyme EX2003
Merck v. Halozyme
IPR2026-00312

U.S. Patent No. 7,863,249

U.S. Patent No. 7,378,508

EMEND®

(aprepitant) Capsules 125/80 mg

U.S. Patent No. 8,258,132

EMEND®

(aprepitant) Capsules 40mg

U.S. Patent No. 8,258,132

EMEND®

(aprepitant) for oral suspension (125 mg)

U.S. Patent No. 8,258,132

ISENTRESS®

(raltegravir) Chewable Tablets for oral use

U.S. Patent No. 7,754,731

U.S. Patent No. 8,771,733

ISENTRESS®

(raltegravir) Film-coated Tablets for oral use

U.S. Patent No. 7,754,731

U.S. Patent No. 8,771,733

JANUMET®

(sitagliptin/metformin HCl) Tablets

U.S. Patent No. 7,326,708

JANUMET® XR

(sitagliptin and metformin HCl extended-release) Tablets

U.S. Patent No. 7,326,708

JANUVIA®

(sitagliptin) Tablets

U.S. Patent No. 7,326,708

JUVISYNC

(sitagliptin and simvastatin) Tablets

U.S. Patent No. 7,326,708

KEYTRUDA QLEX™

(pembrolizumab and berahyaluronidase alfa-pmph) injection, for subcutaneous use

U.S. Patent No. 8,354,509

U.S. Patent No. 8,900,587

U.S. Patent No. 9,834,605

U.S. Patent No. 11,117,961

U.S. Patent No. 12,371,683

U.S. Patent No. 11,633,476

KEYTRUDA®

(pembrolizumab) For Injection

U.S. Patent No. 8,354,509

U.S. Patent No. 8,900,587

U.S. Patent No. 9,834,605

U.S. Patent No. 11,117,961

U.S. Patent No. 9,220,776

LAGEVRIO™

(molnupiravir) Capsules 200mg

U.S. Patent No. 11,331,331

OHTUVAYRE™

(ensifentrine) inhalation suspension, for oral inhalation use

U.S. Patent No. 9,062,047

U.S. Patent No. 9,956,171

U.S. Patent No. 10,945,950

U.S. Patent No. 12,251,384

U.S. Patent No. 12,409,180

PIFELTRO®

(Doravirine) Tablets

U.S. Patent No. 8,486,975

PREVYMIS®

(letermovir) injection, for intravenous use

U.S. Patent No. 8,513,255

PREVYMIS®

(letermovir) Tablets, for Oral Use

U.S. Patent No. 8,513,255

RECARBRIO®

(imipenem/cilastatin and relebactam) For intravenous use

U.S. Patent No. 8,487,093

SEGLUROMET®

(ertugliflozin and metformin) Tablets for oral use

U.S. Patent No. 8,080,580

SIVEXTRO®

(tedizolid phosphate) Powder for Infusion and Oral tablets

U.S. Patent No. 7,816,379

U.S. Patent No. 8,420,676

STEGLATRO®

(ertugliflozin) Tablets for oral use

U.S. Patent No. 8,080,580

STEGLUJAN®

(ertugliflozin and sitagliptin) Tablets for oral use

U.S. Patent No. 8,080,580

VERQUVO®

VERQUVO® (vericiguat) tablets, for oral use

U.S. Patent No. 8,420,656

U.S. Patent No. 10,736,896

WELIREG™

(belzutifan)

U.S. Patent No. 9,908,845

U.S. Patent No. RE49,948

WINREVAIR™

(sotatercept) For Injection

U.S. Patent No. 7,612,041

U.S. Patent No. 7,951,771

ZEPATIER®

(elbasvir/grazoprevir) Tablets for oral use

U.S. Patent No. 8,871,759

U.S. Patent No. 7,973,040

ZERBAXA®

(ceftolozane sulfate/tazobactam sodium) Powder for infusion

U.S. Patent No. 7,129,232

ZINPLAVA™

(bezlotoxumab) Injection, for intravenous use

U.S. Patent No. 8,257,709

ZOLINZA®

(vorinostat) Capsules

U.S. Patent No. 7,456,219

U.S. Patent No. 8,093,295

Revised Date: January 2026

Related links



How we invent

Our teams of scientists bring together diverse expertise and background, combined with cutting-edge technologies, to help discover the next scientific breakthrough for patients.



Sustainability

We operate responsibly every day to enable a safe and healthy future for people and communities globally.



Research

We believe research is the will to conquer the impossible and that science will lead the way.

Connect with us on social



For patients and health care professionals



Sustainability



About Merck



[Forward-looking statement](#) · [Cookie policy](#) · [Cookie Preferences](#) · [Privacy](#) · [Transparency disclosure](#) · [Terms of use](#) · [Accessibility](#) · [Sitemap](#) · [Consumer Health Data Privacy Policy](#) · [Your Privacy Choices](#) 

Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.

